Skip to main content
TipRanks
Go Ultimate75% OFF

Immuneering (IMRX) AI Stock Analysis

695 Followers
IMRX

Immuneering

(NASDAQ:IMRX)

Select Model
Rating:47Neutral
Price Target:$3.50â–¼(-5.66% Downside)
Action:reiterated
Date:10/30/26

The score is primarily weighed down by weak financial performance—zero revenue, sizable ongoing losses, and persistent cash burn (with an extremely negative TTM cash flow figure in the provided data). Technicals are mixed with a small near-term improvement (above the 20-day average) but a still-bearish longer-term trend (below 50/100/200-day averages). Valuation is hard to assess given negative earnings and no dividend yield support.

Positive Factors
Low LeverageVery low leverage reduces solvency pressure and preserves financial flexibility while the company funds clinical development. With limited debt obligations relative to equity, Immuneering has less refinancing exposure and more capacity to direct resources toward advancing its oncology pipeline.
Negative Factors
No Recent RevenueZero revenue means the company currently lacks an operating revenue base to offset research and development spending. Continued dependence on financing or other capital resources increases execution pressure and leaves future financial strength highly dependent on clinical progress.

Immuneering (IMRX) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%IMRX-48.26%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$240.27M
Dividend Yield
―
Average Volume (3M)
709.75K
Price to Earnings (P/E)
-3.6
Beta (1Y)
1.64
Revenue Growth
―
EPS Growth
42.34%
Country
US
Employees
65
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Immuneering Business Overview & Revenue Model

Company Description

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-M...

Immuneering Earnings Call Summary

Earnings Call Date:Nov 12, 2025(Q3-2025)|% Change Since:-43.96%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.

Positive Updates

Extraordinary Overall Survival in Pancreatic Cancer
In September, Immuneering Corporation announced 86% overall survival at nine months in 34 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine nab-paclitaxel, compared to approximately 47% with the standard of care.

Negative Updates

Challenges with FOLFIRINOX Combination
While demonstrating potential, the FOLFIRINOX combination is not currently prioritized due to harsher side effects, limiting its use to younger, higher fitness patients.

Company Guidance

During the Immuneering Corporation's third-quarter 2025 conference call, CEO Benjamin Zeskind highlighted notable guidance for the company's development plans, focusing on their Phase IIa trial of atebimetinib. Immuneering plans to prioritize atebimetinib in combination with gemcitabine nab-paclitaxel due to its impressive 86% overall survival rate at nine months in first-line pancreatic cancer patients, compared to the standard 47%. The company aims to present updated results at a major medical meeting in 2026. Financially, Immuneering strengthened its position with $225 million in cumulative financing, extending its cash runway into 2029, which supports the planned pivotal Phase III trials and other developments. Additionally, the company is preparing to dose the first patient in a pivotal trial in mid-2026 and has planned studies with Regeneron and Eli Lilly, indicating broad potential for atebimetinib across various cancer types.

Immuneering Financial Statement Overview

Summary

Overall financial profile is weak: revenue has fallen to zero in recent periods and losses remain sizable (TTM net income about -$66.5M). Cash flow is a major headwind with persistent negative operating/free cash flow and an extreme TTM deterioration in cash flow figures (noted as a possible anomaly, but still concerning based on provided data). The key offset is a relatively strong balance sheet with very low leverage (~$3.5M debt vs. ~$168.7M equity; ~0.02 debt-to-equity).

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue0000316.95K2.08M
Gross Profit-983.22K-698.89K00158.83K926.89K
EBITDA-72.11M-55.67M-63.69M-58.06M-51.47M-33.68M
Net Income-66.50M-56.02M-61.04M-53.47M-50.51M-33.54M
Balance Sheet
Total Assets182.56M231.99M52.71M102.58M122.37M166.70M
Cash, Cash Equivalents and Short-Term Investments145.41M172.83M36.14M85.67M105.52M149.20M
Total Debt3.53M3.82M4.16M4.46M4.84M5.36M
Total Liabilities13.88M13.50M11.33M12.01M12.52M10.72M
Stockholders Equity168.68M218.48M41.39M90.58M109.85M155.98M
Cash Flow
Free Cash Flow-61.81M-45.49M-55.08M-49.31M-44.84M-30.91M
Operating Cash Flow-61.56M-45.34M-55.00M-48.97M-44.10M-30.85M
Investing Cash Flow-107.84M-88.74M26.43M7.30M41.83M-75.62M
Financing Cash Flow68.02K226.58M5.30M28.44M19.00K144.26M

Immuneering Technical Analysis

Technical Analysis SentimentNegative
Last Price3.71

Price Trends

50DMA4.00Negative
100DMA4.42Negative
200DMA4.74Negative

Market Momentum

MACD-0.08Negative
RSI47.40Neutral
STOCH58.15Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Negative. The current price of 3.71 is below the 20-day moving average (MA) of 3.73, below the 50-day MA of 4.00, and below the 200-day MA of 4.74, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.40 is Neutral, neither overbought nor oversold. The STOCH value of 58.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRX.

Immuneering Risk Analysis

Immuneering disclosed 90 risk factors in its most recent earnings report. Immuneering reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.Q3, 2024
2.We have broad discretion in the use of our cash reserves and may not use them effectively.Q4, 2023
3.Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.Q4, 2023

Immuneering Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IMRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IMRXIMRX47Neutral$240.27M-3.60-33.91%――42.34%
LRMRLRMR46Neutral$313.73M-1.52-137.39%――-27.00%
RCKTRCKT42Neutral$256.82M-16.43-5.34%――93.49%
AURAAURA41Neutral$739.97M-4.26-64.69%――13.33%
IVVDIVVD41Neutral$171.58M-1.48-59.73%―26.30%59.47%

* Healthcare Sector Average

Performance Comparison

-50%0%50%IMRXLRMRRCKTIVVDAURADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IMRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IMRXImmuneering Corp. Class A3.71-3.44-48.11%
LRMRLarimar Therapeutics, Inc.3.02-0.37-10.91%
RCKTRocket Pharma2.30-0.64-21.77%
IVVDInvivyd0.58-1.95-77.00%
AURAAura Biosciences Inc7.111.7031.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026